Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)

Dana E. Rathkopf, Matthew R. Smith, Johann S. De Bono, Christopher J. Logothetis, Neal D. Shore, Paul De Souza, Karim Fizazi, Peter F.A. Mulders, Paul Mainwaring, John D. Hainsworth, Tomasz M. Beer, Scott North, Yves Fradet, Hendrik Van Poppel, Joan Carles, Thomas W. Flaig, Eleni Efstathiou, Evan Y. Yu, Celestia S. Higano, Mary Ellen TaplinThomas W. Griffin, Mary B. Todd, Margaret K. Yu, Youn C. Park, Thian Kheoh, Eric J. Small, Howard I. Scher, Arturo Molina, Charles J. Ryan, Fred Saad

    Research output: Contribution to journalArticleResearchpeer-review

    236 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)'. Together they form a unique fingerprint.

    Medicine and Dentistry

    Pharmacology, Toxicology and Pharmaceutical Science

    Immunology and Microbiology

    Biochemistry, Genetics and Molecular Biology

    Nursing and Health Professions